A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
The best Bull and Bear pitches based on recency and number of recommendations.
I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock… More
Read the most recent pitches from players about ARQL.DL.
Find the members with the highest scoring picks in ARQL.DL.
See what the Wall Street professionals think, according to their public statements and filings.